--- title: "Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each" url: "https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-04-03" section: "Financings" tickers: "NASDAQ:ENTX" source: "https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm" summary: "Entera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement a" --- By the aibio.space news desk. Sources - [Entera Bio Ltd. Form 8-K filed April 3, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm) - [zk2634461.htm](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/zk2634461.htm) - [Entera Bio Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/) [ENTX](https://aibio.space/companies/entera-bio/) 2026-04-03 # Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each in private placement Tickers [ENTX](https://aibio.space/companies/entera-bio/) Entera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026. ## Key facts - **Company**: Entera Bio Ltd. (NASDAQ: ENTX) - **News type**: Financings - **Primary source**: [Entera Bio Ltd. Form 8-K filed April 3, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm) *Glass office towers seen from below. CC0, via rawpixel. The picture shows the field, not the companies named.* Entera Bio Ltd. (Nasdaq: [ENTX](https://aibio.space/companies/entera-bio/)) sold 7,827,789 units in a private placement to funds affiliated with BVF Partners LP. The company reported the deal in a [Form 8-K filed April 3, 2026](https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm) under Item 1.01. It signed the Securities Purchase Agreement on April 1, 2026, and the closing took place on April 2, 2026. The units were priced at $1.2775 each, for aggregate proceeds of about $10.0 million. Miranda Toledano, Chief Executive Officer, signed the report. ## Who arranged the deal The 8-K names the BVF-affiliated funds as the only purchaser group. It names no placement agent, bank, underwriter, financial adviser or counsel for the placement, and the filing does not describe any fee paid to an intermediary. ## What each unit contains Each unit consists of one ordinary share, or one pre-funded warrant to buy one ordinary share in its place, and one warrant to buy one and a half ordinary shares. The purchaser elected to receive a mix of ordinary shares and pre-funded warrants. The ordinary shares carry a par value of NIS 0.0000769. Pre-funded warrants are priced almost entirely up front, so exercising one costs only a nominal amount, here NIS 0.0000769 per ordinary share. They are immediately exercisable and have no expiration date. The ordinary share warrants have an exercise price of $1.24 a share. They become exercisable six months after the closing and expire five years after issue. Subject to the availability of an effective registration statement for resale of the underlying shares, they may be exercised only for cash. If all of them were exercised for cash, the company says it would receive about $14.5 million more. Both warrant types have a 4.99% beneficial ownership cap, which the holder may raise to no more than 19.99%. ## Registration and resale The securities were offered under the exemption in Section 4(a)(2) of the Securities Act of 1933. The company relied in part on the purchaser's representations, including that it is an accredited investor. Under the Registration Rights Agreement, Entera must file a registration statement covering resale of the shares in the units and the shares issuable on exercise within 30 days after the closing date. It must use reasonable best efforts to have that statement declared effective as promptly as possible. Until a registration statement is effective, holders may exercise the ordinary share warrants on a cashless basis. ## Use of the money Entera says it will use the net proceeds to support the start of its phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, and for working capital and general corporate purposes. The 8-K does not give net proceeds after expenses. ## The company's position Entera describes itself in its 10-K as a clinical-stage company developing oral tablet formats of peptides and protein replacement therapies, built on its N-Tab platform. Its most advanced candidate is EB613, an oral teriparatide that it is developing as a tablet treatment for osteoporosis under a 505(b)(2) application that refers to Forteo, which the FDA first approved in 2002. The 10-K is the more pressing document for this deal. It says management's analysis shows current cash resources should fund operating expenses through the middle of the third quarter of 2026, excluding the initiation of the Phase 3 study of EB613. It also says that, because of recurring losses, substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the date of the report. The 10-K lists the company's ability to raise additional funds among its forward-looking risks. ## What the placement leaves open At $1.2775 a unit, the offering's cash is small against a phase 3 study that the proceeds are meant to help start. The units also come with warrants that would add more cash only if the stock trades above $1.24 and the holder chooses to exercise for cash. The 8-K ties the warrant cash to an effective registration statement, and the filing gives no date for one. Until a registration statement covers the shares, the warrants may be exercised only on a cashless basis, which brings in no cash. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ENTX Entera Bio Ltd. NASDAQ ยท Israel Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Entera Bio sells 7,827,789 units to BVF-affiliated funds at $1.2775 each", 2026-04-03, https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/